Please assess the completion status of the following clinical trial:

Trial Title: Cingal Study for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is 40 - 75 years old with a Body Mass Index (BMI)≤ 40 kg/m2~* Subject has Kellgren-Lawrence (K-L) severity grade I, II, or III in the index knee as determined by X-Ray. Contralateral knee: K-L severity grade 0, I, or II.~Exclusion Criteria:~* Subject received an intra-articular (IA) injection of Hyaluronic Acid (HA) and/or steroid in either knee within 6 months of signing the informed consent form (ICF).~* Subject had an arthroscopy of either knee within 3 months of signing the informed consent form (ICF).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): Single injection of 0.9% saline supplied as a 4 milliliter (mL) unit dose in a 5mL glass syringe
- Hyaluronic Acid and TH (Cingal®) (Type: EXPERIMENTAL): Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
- Hyaluronic Acid (Monovisc®) (Type: ACTIVE_COMPARATOR): Single injection of sodium hyaluronate supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe

Based on this trial design, predict the completion outcome and termination type (if applicable).